Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review

doi:10.12998/wjcc.v7.i21.3486

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 21

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10578)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

911

WORD

213

HTML

5115

Figures (1-1)

293

Tables (1-7)

288

Sum=6820

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

770

Download

1084

Sum=1854

Publishing Process of This Article

Item

Count

Browse

723

Download

1181

Sum=1904

Nov 6, 2019 (publication date) through Jan 31, 2025

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Review

World J Clin Cases. Nov 6, 2019; 7(21): 3486-3504
Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3486

Table 2 Strengths of recommendations regarding pharmacological interventions for irritable bowel syndrome in 20 clinical practice guidelines

	Drugs	Recommendations by CPGs
Pain	Antispasmodics	Strongly recommended or recommended by 13 CPGs; weak evidence reported by 1 CPG
	Peppermint oil	Strongly recommended or recommended by 4 CPGs
	TCAs¹	Strongly recommended or recommended by 10 CPGs; weak evidence reported by 3 CPG
	SSRIs	Strongly recommended or recommended by 10 CPGs; weak evidence reported by 3 CPG
Diarrhea	Loperamide	Recommended by 9 CPGs; weak evidence reported by 3 CPG
	Alosetron²	Strongly recommended or recommended by 7 CPGs
	Eluxadoline	Strongly recommended by 1 CPG; insufficient evidence reported by 1 CPG
Constipation	Mosapride	Recommended by 1 CPG
	Prucalopride	Insufficient evidence reported by 5 CPGs
	PEG	Recommended by 6 CPGs; weak evidence reported by 1 CPG; insufficient evidence reported by 7 CPGs³
	Linaclotide	Strongly recommended or recommended by 7 CPGs
	Lubiprostone	Strongly recommended by 6 CPGs; insufficient evidence reported by 1 CPG
Global symptoms	Probiotics	Strongly recommended or recommended by 6 CPGs; weak or insufficient evidence reported by 5 CPG
Global symptoms	Rifaximin	Recommended by 6 CPGs; weak or insufficient evidence reported by 5 CPG

¹TCAs should be avoided in irritable bowel syndrome-C patients;

²Alosetron should only be used in women with severe irritable bowel syndrome-D;

³PEG was considered to have insufficient evidence regarding global symptom improvement.

TCAs: Tricyclic antidepressants; PEG: Polyethylene glycol; CPG: Clinical practice guidelines.

Citation: Dai L, Zhong LL, Ji G. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review. World J Clin Cases 2019; 7(21): 3486-3504
URL: https://www.wjgnet.com/2307-8960/full/v7/i21/3486.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i21.3486